Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.jviromet.2020.113970 http://scihub22266oqcxt.onion/10.1016/j.jviromet.2020.113970 32920028!7482591!32920028     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Virol+Methods 2020 ; 285 (ä): 113970 Nephropedia Template TP {{tp|p=32920028|t=2020. Comparison of commercial assays and laboratory developed tests for detection of SARS-CoV-2 |pdf=|usr=}}{{32920028}} gab.com Text Comparison of commercial assays and laboratory developed tests for detection of SARS-CoV-2 JO: J Virol Methods http://www.kidney.de/pget.php?&tw=1&pmid=32920028 #FOAvip The global COVID-19 pandemic has led to the rapid development of tests for detection of SARS-CoV-2. Studies are required to assess the relative performance of different assays. Here, we compared the performance of two commercial assays, the cobas(R) SARS-CoV-2 (Roche Diagnostics) and Xpert(R) Xpress SARS-CoV-2 (Cepheid(R)) tests, and a laboratory developed RT-PCR test adapted for use on the Hologic(R) Panther Fusion(R) (Hologic(R)) instrument as well as Bio-Rad and QIAGEN real-time PCR detection systems. Performance characteristics for each test were determined by testing clinical specimens and reference material. All assays detect the pan-Sarbecovirus E (envelope structural protein) gene plus a SARS-CoV-2-specific target. The limit of detection for the E gene target varied from approximately 2 copies/reaction to >30 copies/reaction. Due to assay-specific differences in sample processing and nucleic acid extraction, the overall analytical sensitivity ranged from 24 copies/mL specimen to 574 copies/mL specimen. Despite these differences, there was 100 % agreement between the commercial and laboratory developed tests. No false-negative or false-positive SARS-CoV-2 results were observed and there was no cross-reactivity with common respiratory viruses, including endemic coronaviruses. Twit Text FOAVip Comparison of commercial assays and laboratory developed tests for detection of SARS-CoV-2 ????J Virol Methods http://www.kidney.de/pget.php?&tw=1&pmid=32920028 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32920028 #FOAvip English Wikipedia <ref>{{Cite pmid|32920028}}</ref> Comparison of commercial assays and laboratory developed tests for detection of SARS-CoV-2 #MMPMID32920028 Dust K; Hedley A; Nichol K; Stein D; Adam H; Karlowsky JA; Bullard J; Van Caeseele P; Alexander DC J Virol Methods 2020[Nov]; 285 (ä): 113970 PMID32920028show ga The global COVID-19 pandemic has led to the rapid development of tests for detection of SARS-CoV-2. Studies are required to assess the relative performance of different assays. Here, we compared the performance of two commercial assays, the cobas(R) SARS-CoV-2 (Roche Diagnostics) and Xpert(R) Xpress SARS-CoV-2 (Cepheid(R)) tests, and a laboratory developed RT-PCR test adapted for use on the Hologic(R) Panther Fusion(R) (Hologic(R)) instrument as well as Bio-Rad and QIAGEN real-time PCR detection systems. Performance characteristics for each test were determined by testing clinical specimens and reference material. All assays detect the pan-Sarbecovirus E (envelope structural protein) gene plus a SARS-CoV-2-specific target. The limit of detection for the E gene target varied from approximately 2 copies/reaction to >30 copies/reaction. Due to assay-specific differences in sample processing and nucleic acid extraction, the overall analytical sensitivity ranged from 24 copies/mL specimen to 574 copies/mL specimen. Despite these differences, there was 100 % agreement between the commercial and laboratory developed tests. No false-negative or false-positive SARS-CoV-2 results were observed and there was no cross-reactivity with common respiratory viruses, including endemic coronaviruses. |*Betacoronavirus/genetics/immunology[MESH] |*Clinical Laboratory Techniques/methods/standards[MESH] |*Molecular Diagnostic Techniques/methods/standards[MESH] |*Reagent Kits, Diagnostic/standards[MESH] |COVID-19[MESH] |COVID-19 Testing[MESH] |COVID-19 Vaccines[MESH] |Coronavirus Infections/*diagnosis/*virology[MESH] |Humans[MESH] |Pandemics[MESH] |Pneumonia, Viral/*diagnosis/*virology[MESH] |SARS-CoV-2[MESH]Comparison of commercial assays and laboratory developed tests for det(epmc).pdf DeepDyve Pubget Overpricing